Literature DB >> 19306035

Hypermetabolism in ALS patients: an early and persistent phenomenon.

C Bouteloup1, J-C Desport, P Clavelou, N Guy, H Derumeaux-Burel, A Ferrier, P Couratier.   

Abstract

The malnutrition common among patients with ALS can be attributed in some cases to increased resting energy expenditure (REE). However, the origins and evolution of this hypermetabolism have yet to be fully elucidated. The aim of the present study was to monitor REE over time in patients with ALS and to identify factors that may explain any variation observed. ALS patients underwent nutritional, neurological and respiratory assessment every 6 months for 2 years (or until they died or became physically incapable of being examined). Sixty-one patients were studied. At inclusion, 47.5% exhibited hypermetabolism, with a mean measured REE (mREE) 19.7 +/- 6.4% higher than the mean calculated REE (cREE) (P < 0.0001). The hypermetabolism persisted when mREE was normalized for fat free mass (FFM): 35.1 +/- 4.2 versus 32.3 +/- 4.7 kcal/kg day(-1) (P = 0.02) in hypermetabolic and normometabolic patients, respectively. In univariate analysis, mREE was negatively correlated with age and positively correlated with BMI, FFM, energy and protein intakes, and albumin level. No correlation was found with neurological scores, disease characteristics, respiratory function and survival. Multivariate analysis revealed no significant factors. Only 10 of 45 patients in whom REE was measured at least twice changed their metabolic status. Neither mREE nor mREE/cREE varied significantly over time, despite deteriorating neurological, nutritional and respiratory parameters (P < 0.0001), and an increase in mREE/FFM (P = 0.01). This study confirms that about 50% of ALS patients are hypermetabolic, and 80% show no change in metabolic status over time. Thus, metabolic status (a clinically useful indicator of the need for nutritional support) can be determined early in the evolution of the disease. The origin of hypermetabolism in this context remains unknown, but growing evidence points to mitochondria as having an important role.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19306035     DOI: 10.1007/s00415-009-5100-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Standard equations are not accurate in assessing resting energy expenditure in patients with amyotrophic lateral sclerosis.

Authors:  Michael S Sherman; Ajay Pillai; Ann Jackson; Terry Heiman-Patterson
Journal:  JPEN J Parenter Enteral Nutr       Date:  2004 Nov-Dec       Impact factor: 4.016

2.  Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis.

Authors:  F R Wiedemann; K Winkler; A V Kuznetsov; C Bartels; S Vielhaber; H Feistner; W S Kunz
Journal:  J Neurol Sci       Date:  1998       Impact factor: 3.181

3.  El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors.

Authors:  B R Brooks
Journal:  J Neurol Sci       Date:  1994-07       Impact factor: 3.181

4.  Nutritional status is a prognostic factor for survival in ALS patients.

Authors:  J C Desport; P M Preux; T C Truong; J M Vallat; D Sautereau; P Couratier
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

5.  Hypermetabolism in ALS: correlations with clinical and paraclinical parameters.

Authors:  Jean-Claude Desport; Frédéric Torny; Mathieu Lacoste; Pierre-Marie Preux; Philippe Couratier
Journal:  Neurodegener Dis       Date:  2005       Impact factor: 2.977

6.  Amyotrophic lateral sclerosis. A study of its presentation and prognosis.

Authors:  S S Gubbay; E Kahana; N Zilber; G Cooper; S Pintov; Y Leibowitz
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

7.  Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber.

Authors:  E Ravussin; S Lillioja; T E Anderson; L Christin; C Bogardus
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

8.  [Energy metabolism of ALS patients under mechanical ventilation and tube feeding].

Authors:  T Shimizu; H Hayashi; H Tanabe
Journal:  Rinsho Shinkeigaku       Date:  1991-03

9.  Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model.

Authors:  Luc Dupuis; Hugues Oudart; Frédérique René; Jose-Luis Gonzalez de Aguilar; Jean-Philippe Loeffler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-19       Impact factor: 11.205

10.  Nutritional considerations in the management of patients with amyotrophic lateral sclerosis (ALS).

Authors:  L A Slowie; M S Paige; J P Antel
Journal:  J Am Diet Assoc       Date:  1983-07
View more
  98 in total

1.  Antecedent Disease is Less Prevalent in Amyotrophic Lateral Sclerosis.

Authors:  Cassie S Mitchell; Sabrina K Hollinger; Shivani D Goswami; Meraida A Polak; Robert H Lee; Jonathan D Glass
Journal:  Neurodegener Dis       Date:  2015-02-20       Impact factor: 2.977

2.  Early ALS-type gait abnormalities in AMP-dependent protein kinase-deficient mice suggest a role for this metabolic sensor in early stages of the disease.

Authors:  Maxime Vergouts; Claudia Marinangeli; Caroline Ingelbrecht; Geraldine Genard; Olivier Schakman; Anthony Sternotte; André-Guilhem Calas; Emmanuel Hermans
Journal:  Metab Brain Dis       Date:  2015-07-09       Impact factor: 3.584

3.  Prediagnostic body size and risk of amyotrophic lateral sclerosis death in 10 studies.

Authors:  Éilis J O'Reilly; Molin Wang; Hans-Olov Adami; Alvaro Alonso; Leslie Bernstein; Piet van den Brandt; Julie Buring; Sarah Daugherty; Dennis Deapen; D Michal Freedman; Dallas R English; Graham G Giles; Niclas Håkansson; Tobias Kurth; Catherine Schairer; Elisabete Weiderpass; Alicja Wolk; Stephanie A Smith-Warner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2018-04-16       Impact factor: 4.092

4.  Body mass index delineates ALS from FTD: implications for metabolic health.

Authors:  R M Ahmed; E Mioshi; J Caga; M Shibata; M Zoing; L Bartley; O Piguet; J R Hodges; M C Kiernan
Journal:  J Neurol       Date:  2014-06-24       Impact factor: 4.849

5.  Statistical insights into major human muscular diseases.

Authors:  Shakti Gupta; Sung-Min Kim; Yu Wang; Ashok Reddy Dinasarapu; Shankar Subramaniam
Journal:  Hum Mol Genet       Date:  2014-02-25       Impact factor: 6.150

6.  Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference?

Authors:  Ji Won Yang; Sung-Min Kim; Hee-Juang Kim; Jee-Eun Kim; Kyung Seok Park; Seung-Hyun Kim; Kwang-Woo Lee; Jung-Joon Sung
Journal:  J Clin Neurol       Date:  2013-04-04       Impact factor: 3.077

7.  Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease.

Authors:  M A Lim; M A Selak; Z Xiang; D Krainc; R L Neve; B C Kraemer; J L Watts; R G Kalb
Journal:  J Neurosci       Date:  2012-01-18       Impact factor: 6.167

8.  An exploratory study of the association between thyroid hormone and survival of amyotrophic lateral sclerosis.

Authors:  Zhenzhen Zheng; Xiaoyan Guo; Rui Huang; Xueping Chen; Huifang Shang
Journal:  Neurol Sci       Date:  2014-02-07       Impact factor: 3.307

9.  Acyl coenzyme A thioesterase 7 regulates neuronal fatty acid metabolism to prevent neurotoxicity.

Authors:  Jessica M Ellis; G William Wong; Michael J Wolfgang
Journal:  Mol Cell Biol       Date:  2013-03-04       Impact factor: 4.272

10.  Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status.

Authors:  Christian Lunetta; Andrea Lizio; Lucio Tremolizzo; Massimiliano Ruscica; Chiara Macchi; Nilo Riva; Patrick Weydt; Ettore Corradi; Paolo Magni; Valeria Sansone
Journal:  J Neurol       Date:  2018-10-22       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.